GSK Says Lung Cancer Drug Extended Survival in China Trial
2026-07-10 12:07:04
GSK Plc said an experimental lung cancer drug it is developing with Hansoh Pharmaceutical Group helped patients with small-cell lung cancer live longer in a late-stage trial in China, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
